Boston Scientific Corporation · NYSE:BSX
Boston Scientific — North American Neuromodulation Society (NANS) 2019
15 slides from Boston Scientific's conference presentation, Jan 18, 2019
Slide 1: Investor Update at North American Neuromodulation Society
Investor Update at North American Neuromodulation Society Maulik Nanavaty, SVP & President, Neuromodulation Jesse Feinkind, Vice President, Global SCS Milad Girgis, Vice President, Global DBS January 18, 2019
Slide 2: Safe Harbor for Forward-Looking Statements & Disclaimers
Safe Harbor for Forward-Looking Statements & Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipat
Slide 3: BSX Neuromodulation: Expanding Leadership in Two Fast-Growth Markets
BSX Neuromodulation: Expanding Leadership in Two Fast-Growth Markets Overview* BSX Growth Drivers Market Size ~$3.3B Proven Spectra WaveWriter™ Therapy Success (2018E) • First and only FDA approved system with Combination Therapy to simultaneously provide paresthesia and sub-perception therapy Marke
Slide 4: Pain: Personalized Therapy to Address the Complexities of Treating Chronic Pain
Pain: Personalized Therapy to Address the Complexities of Treating Chronic Pain Combination Therapy Infinion CX™ Lead Wide Range of Options Cosman RF Ablation Patient Engagement Simultaneously deliver Easier targeting of multiple Options for Patients Broad RF ablation portfolio with (MICC, 32-contac
Slide 5: SCS Therapy Challenges and Opportunities for BSX
SCS Therapy Challenges and Opportunities for BSX Longevity of Therapy Variation in Response Low Therapy Awareness Inadequate pain relief leads to 4.2% industry Multiple studies (PROCO4, SUNBURST12) show An estimated 1 in 5 adults suffer from pain, annual explant rate11 that non-responders to one mod
Slide 6: Spectra WaveWriter SCS System: Delivering Industry Leading Real World Outcomes
Spectra WaveWriter SCS System: Delivering Industry Leading Real World Outcomes Maximize Responder Rates with Combination Therapy WaveWriter Real World Outcomes14 Changes in Overall Pain Scores NRS* 10 NRS Score (0-10) 8 6 p < 0.0001 p < 0.0001 4 7.3 2 1.9 2.1 2.1 Designed to engage multiple mechanis
Slide 7: Accelerating Access to Therapy: Educating and Engaging Patients
Accelerating Access to Therapy: Educating and Engaging Patients 7
Slide 8: Brain Modulation: Most Compelling Portfolio with Differentiated Technology, Strong Clinical Evidence
Brain Modulation: Most Compelling Portfolio with Differentiated Technology, Strong Clinical Evidence Unique Cochlear MICC Personalized Neuro-prosthetic DNA Systems MR Conditional GUIDE XT CE Mark May 2018 Vercise PC US EXPANSION: Vercise Gevia Directional System Vercise PC & Gevia Directional System
Slide 9: Vercise Directional Systems with MICC: Reshaping DBS Therapy with Clinical Evidence
Vercise Directional Systems with MICC: Reshaping DBS Therapy with Clinical Evidence Directional Lead with Single Power Source DBS Therapy Goals Side Effect Structure Accurately target stimulation area and avoid side-effect structures Maintain stimulation in therapeutic zone over time MICC Directiona
Slide 10: One-year INTREPID Data Highlight Technological and Clinical Advantages of BSX DBS Therapies
One-year INTREPID Data Highlight Technological and Clinical Advantages of BSX DBS Therapies Percent of Programs Using Different Stimulation Contacts Improvement in ON Time as Documented by Over Time19 Motor Diary 100% 7 6.0 6 1 Improvement in ON time (hours) 75% 2 5.0 59.3% 5 3 or more Proportion of
Slide 11: Future of Brain Modulation Is Now Bringing Winning Portfolio to the U.S. in 2019
Future of Brain Modulation Is Now Bringing Winning Portfolio to the U.S. in 2019 Vercise DBS Directional Systems with Brainlab® Elements GUIDE XT Visualization Stimview™ Programming Cartesia Lead Precision Control of Directionality Personalizes Programming for Advanced Surgical Planning Captures Out
Slide 12: Neuromodulation: Strong Growth Driven by Meaningful Innovation
Neuromodulation: Strong Growth Driven by Meaningful Innovation • Exciting, large, underpenetrated and high-growth markets • Pain: Leading the industry with innovation focused on personalized therapy – Spectra WaveWriter with Combination Therapy simultaneously delivering paresthesia and sub-perceptio
Slide 13: Boston Scientific NANS 2019
Boston Scientific NANS 2019 Podium Presentations Poster Presentations ePosters A Prospective Global Registry of Real-World Outcomes WHISPER RCT Evaluating Sub-Perception SCS at ≤ 1.2kHz in Real-World Outcomes Using a Novel Directional Lead from Using Spinal Cord Stimulation Systems for Pain Highly D
Slide 14: References
References 1) Neuromodulation reported revenue growth based on preliminary, unaudited sales results issued January 8, 2019. Results are preliminary and subject to completion of year end financial reporting processes, reviews and audit. 2) 1.5 Tesla MRI conditional when all conditions of use are met
Slide 15: References
References 14) North et al., VERITAS: Prospective Multicenter Study of a New SCS System Capable of Multiple Neurostimulation Modalities, NANS 2019 Las Vegas 15) Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry NCT02071134 16) Deep Brain Stimulation (DBS) for the Trea
Boston Scientific — North American Neuromodulation Society (NANS) 2019 on 6ix